Cargando…

Critical Care Management for Novel 2019 SARS-CoV-2 and HCoV-NL63 Coinfection in a Young Immunocompromised Patient: A Chicago Experience

BACKGROUND: SARS-CoV-2 is a newly emerged virus that has spread rapidly, exhibiting tremendous morbidity and mortality. Some potential pharmaceutical targets have been identified but are still lacking proper validation. Case Presentation. We describe the case of a young, immunosuppressed and critica...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanchez-Nadales, Alejandro, Treminio-Quezada, Miguel, Abad, Hasan, Navarro-Motta, Jessica, Contreras-Chavez, Pamela, Kachru, Anil, Chu, Chae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415109/
https://www.ncbi.nlm.nih.gov/pubmed/32802523
http://dx.doi.org/10.1155/2020/8877641
Descripción
Sumario:BACKGROUND: SARS-CoV-2 is a newly emerged virus that has spread rapidly, exhibiting tremendous morbidity and mortality. Some potential pharmaceutical targets have been identified but are still lacking proper validation. Case Presentation. We describe the case of a young, immunosuppressed and critically ill patient with previous Influenza B infection, requiring extracorporeal membrane oxygenation, which was then followed, in the succeeding months, by SARS-CoV-2 infection complicated by severe adult respiratory distress syndrome. Her clinical course exhibited complications, including pulmonary embolism, acute kidney injury, pneumothorax, pneumomediastinum, multiple cardiac arrests, and eventually death. CONCLUSION: Coinfection with other respiratory pathogens and opportunistic infections are possible.